GENERATION AND ISOLATION OF ANTIGEN-SPECIFIC T CELLS

• US 20090137017A1
• Filed: 10/14/2008
• Published: 05/28/2009
• Est. Priority Date: 05/08/2003
• Status: Active Grant

• Current Assignee: Invitrogen Corp. (Thermo Fisher Scientific Incorporated)
• Original Assignee: Invitrogen Corp. (Thermo Fisher Scientific Incorporated)
• Inventors: Bonyhadi, Mark, Kalamasz, Dale
• Granted Patent: US 7,977,095 B2
• Time in Patent Office: Days
• US Class Current: 435/173.100
• CPC Class Codes: A61K 2035/122 for inducing tolerance or supression of immune responses
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 2039/515 Animal cells
• CPC Class Codes: A61K 2039/5158 Antigen-pulsed cells, e.g. T-cells
• CPC Class Codes: A61K 39/4611 T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
• CPC Class Codes: A61K 39/464838 Viral antigens
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/06 for tuberculosis
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 33/00 Antiparasitic agents
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 35/02 : specific for leukemia
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: A61P 37/04 : Immunostimulants
• CPC Class Codes: A61P 7/00 : Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: C12N 2501/515 : CD3, T-cell receptor complex
• CPC Class Codes: C12N 2501/58 : Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
• CPC Class Codes: C12N 2501/599 : with CD designations not provided for elsewhere
• CPC Class Codes: C12N 5/0636 : T lymphocytes

Abstract

The present invention relates generally to methods for generating, expanding, and isolating antigen-specific T cells. Compositions of antigen-specific T cells activated and expanded by the methods herein are further provided.

Claims

1. A method for generating and/or enriching antigen-specific T cells comprising:

(a) exposing a first population of cells wherein at least a portion thereof comprises antigen presenting cells to a surface wherein said surface has antigen attached thereto, such that said surface with antigen attached thereto is ingested by said APC;

(b) exposing a second population of cells wherein at least a portion thereof comprises T cells to the population of cells in part (a);

thereby generating and/or enriching antigen-specific T cells.

2. The method according to claim 1 wherein said APC are in direct contact with said antigen-specific T cells.

3. The method according to claim 2 wherein said APC in direct contact with said antigen-specific T cells are isolated by exposing said APC to a magnetic field.

4. The method according to claim 3 wherein said antigen-specific T cells are expanded according to the following method:

(a) exposing said T cells to an anti-CD3 antibody which is immobilized on a surface; and

(b) stimulating an accessory molecule on the surface of the T cells with an anti-CD28 antibody, wherein said anti-CD28 antibody is immobilized on the same surface as the anti-CD3 antibody;

thereby inducing expansion of said antigen-specific T cells.

5. The method according to claim 4, further comprising exposing said T cells to IL-15.

6. The method according to claim 4, further comprising exposing said T cells to a natural ligand for CD137.

7. The method according to claim 4, further comprising exposing said T cells to an anti-CD137 antibody.

8. The method according to claim 4, further comprising exposing said T cells to an anti-NKG2D antibody or a natural ligand for NKG2D.

9. The method according to claim 3 wherein said antigen-specific T cells are expanded by exposing said antigen-specific T cells to a mitogen.

10. The method according to claim 9 wherein said mitogen is selected from the group consisting of phytohemagglutinin (PHA), phorbol myristate acetate (PMA) and ionomycin, lipopolysaccharide (LPS), and superantigen.

11. The method according to claim 1 wherein said antigen is selected from the group consisting of protein, glycoprotein, peptides, antibody/antigen complexes, whole tumor or virus-infected cells, fixed tumor or virus-infected cells, heat-killed tumor or virus-infected cells, tumor lysate, non-soluble cell debris, apoptotic bodies, necrotic cells, whole tumor cells from a tumor or a cell line that have been treated such that they are unable to continue dividing, allogeneic cells that have been treated such that they are unable to continue dividing, irradiated tumor cells, irradiated allogeneic cells, natural or synthetic complex carbohydrates, lipoproteins, lipopolysaccharides, transformed cells or cell line, transfected cells or cell line, transduced cells or cell line, and virally infected cells or cell line.

12. The method according to claim 1 wherein said antigen is attached to said surface by an antibody/ligand interaction.

13. The method according to claim 12 wherein said antibody/ligand interaction comprises an interaction between an antibody/ligand pair selected from the group consisting of anti-MART-1 antibody/MART-1 antigen, anti-WT-1 antibody/WT-1, anti-PR1 antibody /PR1, anti-PR3 antibody /PR3, anti-tyrosinase antibody/tyrosinase antigen, anti-MAGE-1 antibody/MAGE-1 antigen, anti-MUC-1 antibody/MUC-1 antigen, anti-α

-fetoprotein antibody/α

-fetoprotein antigen, anti-Her2Neu antibody/Her2Neu, anti-HIV gp120 antibody/HIV gp120, anti-influenza HA antibody/influenza HA, anti-CMV pp65/CMV pp65, anti-hepatitis C antibody/hepatitis C proteins, anti-EBV EBNA 3B antibody/EBV EBNA 3B antigen, and anti-human Ig heavy and lignt chains/Ig from a myeloma cancer patient, and anti-human Ig heavy and lignt chains/Ig from a CLL cancer patient.

14. The method according to claim 1 wherein said antigen is chemically attached to said surface.

15. The method according to claim 1 wherein the attachment of said antigen to said surface comprises a biotin-avidin interaction.

16. The method according to claim 1 wherein said population of cells wherein at least a portion thereof comprises APC is derived from a source selected from the group consisting of leukapheresis product, peripheral blood, lymph node, tonsil, thymus, tissue biopsy, tumor, spleen, bone marrow, cord blood, CD34⁺ cells, monocytes, and adherent cells.